Albany Molecular Research completes strategic European acquisition
US-based drug discovery company Albany Molecular Research (AMRI) has successfully completed the acquisition of ComGenex, a privately held drug discovery services company located in Budapest, Hungary, that combines chemical synthesis and computational chemistry to create drug-like compounds.
US-based drug discovery company Albany Molecular Research (AMRI) has successfully completed the acquisition of ComGenex, a privately held drug discovery services company located in Budapest, Hungary, that combines chemical synthesis and computational chemistry to create drug-like compounds.
The acquisition provides AMRI with an immediate presence in Europe which, in combination with its facilities in the US and Asia, enhances the company's ability to offer a range of flexible services and cost models and provides a hub from which to establish additional relationships with European pharmaceutical and biotechnology companies.
Dr Michael A. Guaciaro has assumed leadership responsibility for the Hungarian facilities, while ComGenex ceo Dr Laszlo Urge will remain with AMRI in Budapest and serve as a key member of the leadership team there. Since joining AMRI in 2001, Guaciaro has successfully led more than 40 drug discovery project teams and has played a key role in the support and co-ordination of medicinal chemistry projects at the company's r&d centres in Singapore and India.